Menu Search
Equities

AstraZeneca PLC

AZN:LSE

AstraZeneca PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)12,016.00
  • Today's Change88.00 / 0.74%
  • Shares traded985.81k
  • 1 Year change+9.84%
  • Beta0.3640
Data delayed at least 20 minutes, as of Sep 16 2024 16:23 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy8
Outperform13
Hold6
Sell2
Strong Sell0

Share price forecast in USD

The 26 analysts offering 12 month price targets for AstraZeneca plc have a median target of 13,935.27, with a high estimate of 19,877.27 and a low estimate of 6,095.92. The median estimate represents a 16.83% increase from the last price of 11,928.00.
High66.6%19,877.27
Med16.8%13,935.27
Low-48.9%6,095.92

Dividends in USD

In 2023, AstraZeneca PLC reported a dividend of 2.90 USD, equaling last years dividend. The 23 analysts covering the company expect dividends of 3.12 USD for the upcoming fiscal year, an increase of 7.56%.
Div growth (TTM)0.21%
More ▼

Earnings history & estimates in USD

On Jul 25, 2024, AstraZeneca plc reported 2nd quarter 2024 earnings of 1.98 per share. This result was in line with the consensus of the 13 analysts following the company and under-performed last year's 2nd quarter results by 7.91%.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate+0.62%
AstraZeneca plc reported annual 2023 earnings of 7.26 per share on Feb 08, 2024.
Average growth rate+20.34%
More ▼

Revenue history & estimates in USD

AstraZeneca PLC had 2nd quarter 2024 revenues of 12.94bn. This bettered the 12.63bn consensus of the 14 analysts covering the company. This was 18.93% above the prior year's 2nd quarter results.
Average growth rate+3.20%
AstraZeneca PLC had revenues for the full year 2023 of 45.81bn. This was 3.29% above the prior year's results.
Average growth rate+17.89%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.